AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-18 receptor accessory protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O95256

UPID:

I18RA_HUMAN

Alternative names:

Accessory protein-like; CD218 antigen-like family member B; CDw218b; IL-1R accessory protein-like; Interleukin-1 receptor 7; Interleukin-18 receptor accessory protein-like; Interleukin-18 receptor beta

Alternative UPACC:

O95256; B2RPJ3; Q2QDE5; Q3KPE7; Q3KPE8; Q53TT4; Q53TU5

Background:

The Interleukin-18 receptor accessory protein, known by alternative names such as Accessory protein-like and IL-1R accessory protein-like, plays a crucial role in immune response regulation. It is part of the IL18 receptor complex, facilitating IL18-dependent signal transduction, which activates NF-kappa-B and JNK. This protein is instrumental in IFNG synthesis from T-helper 1 cells, highlighting its significance in immune system functionality.

Therapeutic significance:

Understanding the role of Interleukin-18 receptor accessory protein could open doors to potential therapeutic strategies. Its involvement in key immune response pathways suggests its potential as a target for modulating immune responses in various conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.